Designing a First-in-Human Sequential Single-Dose Study of an Intrathecal Antisense Oligonucleotide in Adults with a Rare Genetic Neurological Disease: Starting-Dose Logic, Cerebrospinal Fluid Sampling, and Phase 1 Protocol Synopsis
An antisense oligonucleotide given into the cerebrospinal fluid reaches the nervous system directly, which changes the first-in-human problem: dose is a total amount in a small compartment, the route itself carries risk, and the earliest evidence of activity comes from a biomarker measured in spinal fluid. This article develops a hypothetical Phase 1 open-label, sentinel-led, sequential single-dose study of an intrathecal oligonucleotide that lowers an astrocyte structural protein in adults with a rare genetic neurological disease caused by a gain-of-function variant. It derives a 5 mg starting dose from assumed exposure modeling, escalates through 5, 10, and 25 mg in three cohorts of three to six participants under 3+3 rules with a 28-day dose-limiting toxicity window, and follows participants to Day 85. The synopsis specifies plasma and cerebrospinal fluid pharmacokinetic and biomarker sampling, lumbar-puncture safety rules, pharmacovigilance timelines, and a descriptive analysis for 9 to 18 participants. It explains why healthy volunteers are not used and why conventional dose scaling must be adapted for a local central nervous system route. All values are illustrative assumptions.Keywords: first-in-human; antisense oligonucleotide; intrathecal; cerebrospinal fluid; target engagement; sentinel dosing; Phase 1 protocol; rare disease
Authors
- Peivand Pirouzi
- Junyi Wu
- Atchaya Ravichandran
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426632
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00